Initial digest — CAMP-LL37 receipt

what this node claims

Initial digest — CAMP-LL37

AlphaFold v6 prediction landed for **CAMP-LL37** (Cathelicidin antimicrobial peptide (LL-37 precursor)). UniProt accession: `P49913`. Lane: `immune_resilience`. Mean per-residue pLDDT: **79.98**. LL-37 is the active 3...

Open source surface

vertical proof spine

evidence / risk instrument

39%

thin proof

low debt pressure 29%

28%structuredebt

pLDDT pending

55%evidencethin

grade C

0%gatesdebt

0/5 gates

100%riskstrong

0 hard flags

22%exportdebt

no export

33%lineagedebt

incomplete spine

proof completeness

33% missing target, alphafold_metric, candidate, export

01 target
02 fold
03 alphafold metric
04 candidate
05 finding
06 export

Metrics and receipt inputs

confidence: 0.6
evidence refs: 1

AlphaFold metrics visual

Confident backbone model

80.0

170 residues / min 38.31 / max 98.12 / source alphafold db

Very high 42.9% 73 residues / >=90

Confident 27.6% 47 residues / 70-89

Low 27.6% 47 residues / 50-69

Very low 1.8% 3 residues / <50

usable fold context with explicit model-confidence limits

Near-complete coverage / observed 170 of 170 residues.

residues 128-149 / mean 55.72
residues 1-10 / mean 55.6
residues 164-170 / mean 59.46
residues 23-29 / mean 65.12

proof debt register

Visible limits, not hidden cleanup.

29%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

high low evidence grade attach graded finding with source-linked evidence

low computational-only status add independent evidence, challenge result, or witness review before strengthening

medium no candidate yet leave visible until a stronger public receipt resolves it

Initial digest — CAMP-LL37